ProBioGen Executes a Master Service Agreement with NextPoint Therapeutics and Starts an Integrated P
BERLIN, Germany and CAMBRIDGE, MA, USA, August 17, 2022 / B3C newswire / -- ProBioGen is delighted to close a Master Service Agreement with NextPoint and initiate development and GMP manufacturing of their lead antibody candidate.ProBioGen's CHO.RiGHT® cell line development including their latest DirectedLuck® trans...